These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29933059)

  • 1. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
    Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
    Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects.
    Lao X; Li B; Liu M; Shen C; Yu T; Gao X; Zheng H
    Apoptosis; 2015 Oct; 20(10):1307-20. PubMed ID: 26283169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1.
    Lao X; Liu M; Chen J; Zheng H
    PLoS One; 2013; 8(8):e72242. PubMed ID: 23977262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a C-end rule modification on antitumor activity of thymosin α1.
    Wang F; Xu C; Peng R; Li B; Shen X; Zheng H; Lao X
    Biochimie; 2018 Nov; 154():99-106. PubMed ID: 30096371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects on tumor growth and immunosuppression of a modified Tα1 peptide along with its circular dichroism spectroscopy data.
    Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
    Data Brief; 2018 Oct; 20():126-131. PubMed ID: 30109250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The anti-tumor efforts of thymosin alpha1 on tumor lysate-pulsed dendritic cells in colon cancer in vitro and in vivo].
    Ma YL; Zheng Z; Li BD; Xie SJ; Li GX; Yan QH; Cai JH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Nov; 23(11):1046-9. PubMed ID: 17988589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.
    Li J; Cheng Y; Zhang X; Zheng L; Han Z; Li P; Xiao Y; Zhang Q; Wang F
    Cancer Lett; 2013 Sep; 337(2):237-47. PubMed ID: 23684552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris.
    Chen JH; Zhang XG; Jiang YT; Yan LY; Tang L; Yin YW; Cheng DS; Chen J; Wang M
    Cancer Immunol Immunother; 2010 Sep; 59(9):1335-45. PubMed ID: 20473755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Historical review on thymosin α1 in oncology: preclinical and clinical experiences.
    Garaci E; Pica F; Matteucci C; Gaziano R; D'Agostini C; Miele MT; Camerini R; Palamara AT; Favalli C; Mastino A; Serafino A; Sinibaldi Vallebona P
    Expert Opin Biol Ther; 2015; 15 Suppl 1():S31-9. PubMed ID: 26096345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased antitumor activity of tumor-specific peptide modified thymopentin.
    Lao X; Li B; Liu M; Chen J; Gao X; Zheng H
    Biochimie; 2014 Dec; 107 Pt B():277-85. PubMed ID: 25236717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
    Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymosin α1 promotes the activation of myeloid-derived suppressor cells in a Lewis lung cancer model by upregulating Arginase 1.
    Yuan C; Zheng Y; Zhang B; Shao L; Liu Y; Tian T; Gu X; Li X; Fan K
    Biochem Biophys Res Commun; 2015 Aug; 464(1):249-55. PubMed ID: 26111447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression, purification and characterization of a novel soluble human thymosin alpha1 concatemer exhibited a stronger stimulation on mice lymphocytes proliferation and higher anti-tumor activity.
    Li W; Song L; Wu S; Xue X; Zhang L; He L; Han W; Wang Q; Ling R; Zhang W; Yan Z; Zhang Y
    Int J Biol Sci; 2011; 7(5):618-28. PubMed ID: 21647330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fusion of thymosin alpha 1 with mutant IgG1 CH3 prolongs half-life and enhances antitumor effects in vivo.
    Shen X; Wang L; Xu C; Yang J; Peng R; Hu X; Wang F; Zheng H; Lao X
    Int Immunopharmacol; 2019 Sep; 74():105662. PubMed ID: 31220695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of thymosin alpha1-thymopentin fusion peptide in Pichia pastoris and its characterization.
    Gao D; Zhang X; Zhang J; Cao J; Wang F
    Arch Pharm Res; 2008 Nov; 31(11):1471-6. PubMed ID: 19023544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with thymosin alpha1 and dexamethasone helps mice survive sepsis.
    Xiang XS; Li N; Zhao YZ; Li QR; Li JS
    Inflammation; 2014 Apr; 37(2):402-16. PubMed ID: 24122349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo.
    Shen X; Li Q; Wang F; Bao J; Dai M; Zheng H; Lao X
    Biomed Pharmacother; 2018 Dec; 108():610-617. PubMed ID: 30243095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymosin alpha1. SciClone Pharmaceuticals.
    Billich A
    Curr Opin Investig Drugs; 2002 May; 3(5):698-707. PubMed ID: 12090542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
    Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
    Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The modulation of thymosin alpha 1 in the maturation, differentiation and function of murine bone marrow-derived dendritic cells in the absence or presence of tumor necrosis factor-alpha.
    Huang Y; Chen Z; Zhou C; Yao H; Li M; Xu C
    Int Immunopharmacol; 2004 Apr; 4(4):539-46. PubMed ID: 15099531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.